VCA Stocks

NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the successful closing of a 37 million Euro (50 million US $) series C round of financing “This impressive investment puts NOXXON in an excellent position to move our lead compounds NOX-E36 for the treatment of lupus nephritis and NOX-A12 for the treatment of diabetic retinopathy into the clinic and through clinical proof of concept”